Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
16 July, 2018 02:42 IST
Lupin receives nod for generic Nitrofurantoin capsules
Source: IRIS | 12 Jul, 2018, 12.39PM
Comments  |  Post Comment

Lupin's Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg is the generic version of Alvogen Malta Operations Macrodantin Capsules, 50 mg and 100 mg. It is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Infosys Q1 profit rises 4% y-o-y to Rs 36.12 bn - 13-Jul-2018 16:45
Fortis accepts Rs 40 bn investment offer from IHH Healthcare Berhad - 13-Jul-2018 10:38
White Organic Agro receives export order for 65 MT of cluster beans - 13-Jul-2018 09:51
Vakrangee partners with Reliance Nippon Life Asset Management - 13-Jul-2018 09:47
Larsen & Toubro wins orders worth Rs 30 bn - 13-Jul-2018 09:41
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA - 12-Jul-2018 13:23
Aban Offshore receives LoA for deployment of 3 jack-up rigs in UAE - 12-Jul-2018 12:26
Sun Pharma arm Dusa files lawsuit against Biofrontera - 12-Jul-2018 11:01
Larsen & Tubro wins orders worth Rs 23.88 bn - 12-Jul-2018 10:51
Alembic Pharma receives USFDA tentative approval for lloperidone Tablets - 12-Jul-2018 10:46
Alembic Pharma gets USFDA tentative approval for Ticagrelor Tablets - 12-Jul-2018 10:40
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer